{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:12Z","timestamp":1793954532746,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study investigated the efficacy of golimumab in the management of refractory non-infectious panuveitis. Nineteen patients (38 eyes; mean age, 31\u00a0years) were retrospectively reviewed between June 2016 and June 2022. All patients had bilateral eye involvement and Beh\u00e7et\u2019s disease was the most common diagnosis (57.9%). Compared to the period before golimumab treatment, the rate of uveitis relapses after golimumab treatment significantly decreased from 1.73 to 0.62 events per person-years (incidence ratio 0.33, 95% confidence interval 0.19\u20130.57, <jats:italic>P\u2009<\/jats:italic>&lt;\u20090.001). After golimumab therapy, 12 patients (63.2%) were able to reduce the number or dosage of immunosuppressive drugs, and the median dosage of systemic corticosteroids was reduced from 15.0 to 7.5\u00a0mg\/d (<jats:italic>P\u2009<\/jats:italic>=\u20090.013) compared to baseline. The median logMAR visual acuity improved from 0.9 at baseline to 0.6 at the last visit (<jats:italic>P\u2009<\/jats:italic>=\u20090.006). Golimumab demonstrated efficacy against refractory non-infectious panuveitis in terms of a corticosteroid-sparing effect and reduced the rate of uveitis relapses to approximately one-third.<\/jats:p>","DOI":"10.1038\/s41598-024-52526-1","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T14:06:57Z","timestamp":1706191617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of golimumab in patients with refractory non-infectious panuveitis"],"prefix":"10.1038","volume":"14","author":[{"given":"Usanee","family":"Tungsattayathitthan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Tesavibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitipol","family":"Choopong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaipat","family":"Treeratsakulchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaninsiri","family":"Ngathaweesuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilawan","family":"Sanphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0215","authenticated-orcid":false,"given":"Sutasinee","family":"Boonsopon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"52526_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","volume":"146","author":"RO Ka\u00e7maz","year":"2008","unstructured":"Ka\u00e7maz, R. O. et al. Ocular inflammation in Beh\u00e7et\u2019s disease: incidence of ocular complications and of loss of visual acuity. Am. J. Ophthalmol. 146, 828\u2013836. https:\/\/doi.org\/10.1016\/j.ajo.2008.06.019 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"52526_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","volume":"123","author":"AD Dick","year":"2016","unstructured":"Dick, A. D. et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 123, 655\u2013662. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.028 (2016).","journal-title":"Ophthalmology"},{"key":"52526_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke, G. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121, 785-796.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048 (2014).","journal-title":"Ophthalmology"},{"key":"52526_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick, A. D. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology 125, 757\u2013773. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.017 (2018).","journal-title":"Ophthalmology"},{"key":"52526_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/ce.s6000","volume":"4","author":"J Kay","year":"2010","unstructured":"Kay, J. & Rahman, M. U. Golimumab: A novel human anti-TNF-\u03b1 monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core. Evid. 4, 159\u2013170. https:\/\/doi.org\/10.2147\/ce.s6000 (2010).","journal-title":"Core. Evid."},{"key":"52526_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","volume":"37","author":"S Yazgan","year":"2017","unstructured":"Yazgan, S. et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int. Ophthalmol. 37, 139\u2013145. https:\/\/doi.org\/10.1007\/s10792-016-0239-y (2017).","journal-title":"Int. Ophthalmol."},{"key":"52526_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3109\/09273948.2013.844265","volume":"22","author":"E Miserocchi","year":"2014","unstructured":"Miserocchi, E., Modorati, G., Pontikaki, I., Meroni, P. L. & Gerloni, V. Long-term treatment with golimumab for severe uveitis. Ocul. Immunol. Inflamm. 22, 90\u201395. https:\/\/doi.org\/10.3109\/09273948.2013.844265 (2014).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"52526_CR8","first-page":"652","volume":"36","author":"N Palmou-Fontana","year":"2018","unstructured":"Palmou-Fontana, N. et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin. Exp. Rheumatol. 36, 652\u2013657 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"52526_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3899\/jrheum.180312","volume":"46","author":"RE van Bentum","year":"2019","unstructured":"van Bentum, R. E. et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab \u2014 the GO-EASY study. J. Rheumatol. 46, 153\u2013159. https:\/\/doi.org\/10.3899\/jrheum.180312 (2019).","journal-title":"J. Rheumatol."},{"key":"52526_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12969-021-00630-1","volume":"19","author":"S Lanz","year":"2021","unstructured":"Lanz, S., Seidel, G. & Skrabl-Baumgartner, A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr. Rheumatol. Online. J. 19, 132. https:\/\/doi.org\/10.1186\/s12969-021-00630-1 (2021).","journal-title":"Pediatr. Rheumatol. Online. J."},{"key":"52526_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","volume":"46","author":"V Calvo-R\u00edo","year":"2016","unstructured":"Calvo-R\u00edo, V. et al. Golimumab in refractory uveitis related to spondyloarthritis. multicenter study of 15 patients. Semin. Arthritis. Rheum. 46, 95\u2013101. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.002 (2016).","journal-title":"Semin. Arthritis. Rheum."},{"key":"52526_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/09273948.2022.2081584","volume":"31","author":"K Okada","year":"2023","unstructured":"Okada, K., Zhou, Y., Hashida, N., Takagi, T. & Tian, Y. S. The efficacy of Golimumab against non-infectious uveitis: a PRISMA-compliant systematic review and meta-analysis. Ocul. Immunol. Inflamm. 31, 1013\u20131023. https:\/\/doi.org\/10.1080\/09273948.2022.2081584 (2023).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"52526_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/09273948.2012.741744","volume":"21","author":"M Mesquida","year":"2013","unstructured":"Mesquida, M. et al. Beh\u00e7et\u2019s disease-associated uveitis successfully treated with golimumab. Ocul. Immunol. Inflamm. 21, 160\u2013162. https:\/\/doi.org\/10.3109\/09273948.2012.741744 (2013).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"52526_CR14","doi-asserted-by":"publisher","first-page":"717598","DOI":"10.1155\/2014\/717598","volume":"2014","author":"M Cordero-Coma","year":"2014","unstructured":"Cordero-Coma, M. et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: A three-center experience. Mediators. Inflamm. 2014, 717598. https:\/\/doi.org\/10.1155\/2014\/717598 (2014).","journal-title":"Mediators. Inflamm."},{"key":"52526_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani, C. et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul. Immunol. Inflamm. 27, 58\u201363. https:\/\/doi.org\/10.1080\/09273948.2017.1351573 (2019).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"52526_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10787-022-01019-6","volume":"30","author":"Y Jin","year":"2022","unstructured":"Jin, Y., Lu, S., Lin, Y. & Mou, X. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology 30, 1363\u20131368. https:\/\/doi.org\/10.1007\/s10787-022-01019-6 (2022).","journal-title":"Inflammopharmacology"},{"key":"52526_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 140, 509\u2013516. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057 (2005).","journal-title":"Am. J. Ophthalmol."},{"key":"52526_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/09273948.2019.1687733","volume":"29","author":"M Pistilli","year":"2021","unstructured":"Pistilli, M. et al. Visual acuity outcome over time in non-infectious uveitis. Ocul. Immunol. Inflamm. 29, 1064\u20131071. https:\/\/doi.org\/10.1080\/09273948.2019.1687733 (2021).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"52526_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/jop.2018.0083","volume":"35","author":"H Celiker","year":"2019","unstructured":"Celiker, H., Kazokoglu, H. & Direskeneli, H. Factors affecting relapse and remission in Beh\u00e7et\u2019s uveitis treated with interferon alpha2a. J. Ocul. Pharmacol. Ther. 35, 58\u201365. https:\/\/doi.org\/10.1089\/jop.2018.0083 (2019).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"52526_CR20","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s00415-021-10787-0","volume":"269","author":"D Sahin Eroglu","year":"2022","unstructured":"Sahin Eroglu, D. et al. Prognostic factors for relapse and poor outcome in neuro-Beh\u00e7et\u2019s syndrome: results from a clinical long-term follow-up of a single centre. J. Neurol. 269, 2046\u20132054. https:\/\/doi.org\/10.1007\/s00415-021-10787-0 (2022).","journal-title":"J. Neurol."},{"key":"52526_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000440646","volume":"6","author":"K Nagata","year":"2015","unstructured":"Nagata, K., Inaba, T. & Kinoshita, S. CD5-positive primary intraocular B-cell lymphoma arising during methotrexate and tumor necrosis factor inhibitor treatment. Case. Rep. Ophthalmol. 6, 301\u2013306. https:\/\/doi.org\/10.1159\/000440646 (2015).","journal-title":"Case. Rep. Ophthalmol."},{"key":"52526_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/ced.12402","volume":"39","author":"S Mateo","year":"2014","unstructured":"Mateo, S., Garc\u00eda-Mart\u00ednez, F. J., S\u00e1nchez-Aguilar, D., Amarelo, J. & Toribio, J. Psoriasiform exfoliative erythroderma induced by golimumab. Clin. Exp. Dermatol. 39, 813\u2013815. https:\/\/doi.org\/10.1111\/ced.12402 (2014).","journal-title":"Clin. Exp. Dermatol."},{"key":"52526_CR23","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.jaad.2012.12.957","volume":"68","author":"LM Madigan","year":"2013","unstructured":"Madigan, L. M., Kaffenberger, B. H. & Wong, H. K. Bullae and psoriasiform hyperkeratosis after treatment with golimumab. J. Am. Acad. Dermatol. 68, e195-196. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.957 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"52526_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","volume":"18","author":"S Segaert","year":"2017","unstructured":"Segaert, S. & Hermans, C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am. J. Clin Dermatol. 18, 771\u2013787. https:\/\/doi.org\/10.1007\/s40257-017-0296-7 (2017).","journal-title":"Am. J. Clin Dermatol."},{"key":"52526_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15859","author":"M Au","year":"2023","unstructured":"Au, M. et al. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm. Intern. Med. J. https:\/\/doi.org\/10.1111\/imj.15859 (2023).","journal-title":"Intern. Med. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52526-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T14:15:12Z","timestamp":1706192112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52526-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52526-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2179"}}